Investigation of Optimal Dosing Conditions for NN9924 in Healthy Male Subjects

• Cmax, Day10: The maximum plasma NN9924 concentration [ Time Frame: After 10 days of dosing ] [ Designated as safety issue: No ]
• tmax, Day10 : Time to maximum plasma NN9924 concentration [ Time Frame: After 10 days of dosing ] [ Designated as safety issue: No ]
• t½, Day10: The terminal half-life of NN9924 [ Time Frame: After 10 days of dosing ] [ Designated as safety issue: No ]

This trial is conducted in Europe. The aim of the trial is to evaluate the optimal dosing conditions for NN9924 in healthy male subjects.

• Diabetes
• Diabetes Mellitus, Type 2
• Healthy

• Drug: NN9924
  Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 120 mins, no food or liquid is allowed.
• Drug: NN9924
  Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 60 mins, no food or liquid is allowed.
• Drug: NN9924
  Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 30 mins, no food or liquid is allowed.
• Drug: NN9924
  Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 15 mins, no food or liquid is allowed.
• Drug: NN9924
  Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 120 mins, no food or liquid is allowed.
• Drug: NN9924
  Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 60 mins, no food or liquid is allowed.
• Drug: NN9924
  Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 30 mins, no food or liquid is allowed.
• Drug: NN9924
  Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 15 mins, no food or liquid is allowed.

• Experimental: Post-dose fasting 120 mins/50 ml water
  Intervention: Drug: NN9924
• Experimental: Post-dose fasting 60 mins/50 ml water
  Intervention: Drug: NN9924
• Experimental: Post-dose fasting 30 mins/50 ml water
  Intervention: Drug: NN9924
• Experimental: Post-dose fasting 15 mins/50 ml water
  Intervention: Drug: NN9924
• Experimental: Post-dose fasting 120 mins/120 ml water
  Intervention: Drug: NN9924
• Experimental: Post-dose fasting 60 mins/120 ml water
  Intervention: Drug: NN9924
• Experimental: Post-dose fasting 30 mins/120 ml water
  Intervention: Drug: NN9924
• Experimental: Post-dose fasting 15 mins/120 ml water
  Intervention: Drug: NN9924

Inclusion Criteria:

• Good general health as judged by the trial physician, based on medical history, physical examination, electrocardiogram (ECG), vital signs and clinical laboratory
• Body mass index (BMI) of 18.5-30.0 kg/m^2 (both inclusive)

Exclusion Criteria:

• Males who are sexually active and not surgically sterilised, who or whose partner(s): a. are not using adequate contraceptive methods (e.g. condom with spermicidal foam/gel/film/cream or contraceptives with a Pearl Index below 1%, such as implants, injectables, combined oral contraceptives, or hormonal intrauterine devices or diaphragm + spermicide) or b. do not refrain from sexual intercourse during the trial and until 30 days following the last dose of trial medication. In addition, subjects must not donate sperm for the duration of the trial and for 30 days following the last dose of trial medication
• Suffer from a life threatening disease or has a history of any clinically significant disease or disorder
• History of acute idiopathic or chronic pancreatitis
• Calcitonin value equal to or above 50 ng/L
• Any clinically significant abnormal laboratory test results (haematology, biochemistry and urinalysis), as judged by the trial physician and any of the following laboratory safety results (based on screening results): Amylase, lipase and creatinine, above upper normal range. Aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT) and gamma-glutamyl-transpeptidase (gamma-GT) above 1.5 times upper normal range (UNR). Thrombocytes below 0.75 times lower normal range (LNR) or above 1.25 times UNR. Leucocytes outside 3.0 to 11.0x10^9/L (normal range is 3.91 to 8.77x10^9/L. Sodium outside the range 130.0 to 150.0 mmol/L (normal range is 136-145 mmol/L). Potassium outside the range 3.0 to 5.5 mmol/L (normal range is 3.5 to 5.1 mmol/L)
• Any clinically significant abnormal electrocardiogram (ECG), as judged by the trial physician
• Subjects who are smokers